Janus kinase inhibitor tofacitinib is a potential therapeutic option for refractory eosinophilic fasciitis.

Cao, Xiao-Yu; Zhao, Jiu-Liang; Hou, Yong; Wang, Feng-Dan; Lu, Zhao-Hui

Cao, Xiao-Yu; Zhao, Jiu-Liang; Hou, Yong; Wang, Feng-Dan; Lu, Zhao-Hui.

Afiliação

Cao XY; Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Zhao JL; Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. zjlpumc@163.com.
Hou Y; Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. houyongjia@hotmail.com.
Wang FD; Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Lu ZH; Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

Clin Exp Rheumatol ; 38(3): 567-568, 2020.

Article em En | MEDLINE | ID: mdl-31820721

Assuntos

Eosinofilia/tratamento farmacológico; Fasciite/tratamento farmacológico; Inibidores de Janus Quinases/uso terapêutico; Piperidinas/uso terapêutico; Pirimidinas/uso terapêutico; Pirróis/uso terapêutico; Idoso; Humanos; Masculino

Buscar no Google

Imprimir

XML

PubMed Links

Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piperidinas / Pirimidinas / Pirróis / Eosinofilia / Fasciite / Inibidores de Janus Quinases Limite: Aged / Humans / Male Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Buscar no Google

Imprimir

XML

PubMed Links